News Column

Researchers from National Health Research Institutes Report on Findings in Doxorubicin Therapy

May 28, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Drugs and Therapies. According to news originating from Miaoli, Taiwan, by NewsRx correspondents, research stated, "Chemotherapy for brain cancer tumors remains a big challenge for clinical medicine due to the inability to transport sufficient drug across the blood brain barrier (BBB) and the poor penetration of drug into the tumors. To effectively treat brain tumors and reduce side effects on normal tissues, both des-octanoyl ghrelin and folate conjugated with polymersomal doxorubicin (GFP-D) was developed in this study to help transport across the BBB and target the tumor as well."

Our news journalists obtained a quote from the research from National Health Research Institutes, "The size measurements revealed that this BBB-penetrating cancer cell-targeting GFP-D was about 85 nm. In-vitro experiments with a BBB model and C6 glioma cells demonstrated that GFP-D owned a robust penetrating-targeting function for drug delivery. In C6 cell viability tests, GFP-D exhibited an inhibitory effect significantly different from the unmodified polymersomal doxorubicin (P-D). In-vivo antitumor experiments showed that GFP-D performed a much better anti-glioma effect and presented a significant improvement in the overall survival of the tumor-bearing mice as compared to the treatments with free doxorubicin (Dox), liposomal doxorubicin (L-D), P-D, or single ligand conjugated P-D. In addition, Cy5.5 was used as a probe to investigate the delivery property of this penetrating-targeting delivery system."

According to the news editors, the research concluded: "The overall experimental results indicate that this BBB-penetrating cancer cell-targeting GFP is a highly potential nanocarrier for the treatment of brain tumors."

For more information on this research see: Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. Biomaterials, 2014;35(13):4066-4081. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)

The news correspondents report that additional information may be obtained from Y.C. Chen, Natl Hlth Res Inst, Div Med Engn Res, Miaoli, Taiwan. Additional authors for this research include C.F. Chiang, L.F. Chen, P.C. Liang, W.Y. Hsieh and W.L. Lin (see also Drugs and Therapies).

Keywords for this news article include: Asia, Antibiotics - Antineoplastics, Pharmaceuticals, Miaoli, Taiwan, Cancer, Ghrelin, Oncology, Chemotherapy, Peptide Hormones, Drugs and Therapies, Doxorubicin Hydrochloride

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters